Home_Test
Pipeline
About Faeth
Clinical Trials
Contact Us

PIPELINE OVERVIEW

Our Pipeline

Our lead program, FTH-001/003, targets the PI3K/AKT/mTOR pathway– the most frequently mutated pathway in cancer.
Product
Candidate(s)
Mechanism
of Action
Indication
Click here to view full program details >
Product
Candidate(s)
FTH-001/003
(Serabelisib + 
Sapanisertib)

Mechanism of Action
“PIKTOR”: PI3Kɑ inhibitor & dual mTORC1/2 inhibitor
Indication
Advanced endometrial cancer
Planned
Complete
Preclinical
Phase 1
Phase 2
Phase 3
Indication
Other undisclosed solid tumors
Complete
Preclinical
Phase 1
Phase 2
Phase 3
Serabelisib (FTH-001)
PI3K-alpha inhibitor
Advanced endometrial cancer
Planned
In Progress
Preclinical
Phase 1
Phase 2
Phase 3
Other advanced solid tumors
In Progress
Preclinical
Phase 1
Phase 2
Phase 3
Product
Candidate(s)
FTH-002

Mechanism of Action
Precise non-essential amino acid restriction
Indication
Rectal Cancer
In Progress
Preclinical
Phase 1
Phase 2
Phase 3
Product
Candidate(s)
Discovery

Mechanism of Action
Metabolic
Indication
Undisclosed advanced solid tumors
In Progress
Preclinical
Phase 1
Phase 2
Phase 3
Product
Candidate(s)
Discovery

Mechanism of Action
Metabolic
Indication
Undisclosed non-oncology indication
In Progress
Preclinical
Phase 1
Phase 2
Phase 3

NEWSLETTER SIGN UP

Stay up to date with Faeth's research

© 2024 Faeth Therapeutics Inc.
Privacy PolicyTerms of Service